Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.

AIDS (London, England) - 1 Oct 2008

Gupta Samir K, Rosenkranz Susan L, Cramer Yoninah S, Koletar Susan L, Szczech Lynda A, Amorosa Valerianna, Hall Stephen D

Abstract excerpt

OBJECTIVE: To evaluate the pharmacokinetics and pharmacogenomics of efavirenz (EFV) and lopinavir/ritonavir (LPV/RTV) in HIV-infected persons requiring hemodialysis. DESIGN: Prospective, observational study of HIV-infected hemodialysis patients receiving one 600 mg tablet daily of EFV (N = 13) or three 133.3/33.3 mg capsules twice daily of LPV/RTV (N = 13). METHODS: Twenty-four-hour EFV and 12-h LPV/RTV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Benzoxazines

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to HIV Protease Inhibitors

Share to Lopinavir

Share to Pyrimidinones

Share to Renal Dialysis

Share to Ritonavir

Source

Open in PubMed Open full text

Identifiers

PMID: 18784455
DOI: 10.1097/QAD.0b013e32830e011f
PMCID: PMC2675161

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.PMID 18784455Read ↗

Safety and Efficacy of Direct-acting Antiviral Therapies for Chronic HCV Infection in Hemodialysis Patients.Semantic proximity Read ↗

Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.Semantic proximity Read ↗

Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.Semantic proximity Read ↗

Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients.Semantic proximity Read ↗

Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.Semantic proximity Read ↗

Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.Semantic proximity Read ↗

Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.Semantic proximity Read ↗

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.Semantic proximity Read ↗

The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.Semantic proximity Read ↗

Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.Semantic proximity Read ↗

Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.